EPIDUO FORTE Drug Patent Profile

Which patents cover Epiduo Forte, and what generic alternatives are available?

Epiduo Forte is a drug marketed by Galderma Labs and is included in one NDA.

The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the adapalene; benzoyl peroxide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Epiduo Forte

A generic version of EPIDUO FORTE was approved as adapalene; benzoyl peroxide by PADAGIS ISRAEL on January 23^rd, 2018.

Summary for EPIDUO FORTE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	31
Patent Applications:	66
Drug Prices:	Drug price information for EPIDUO FORTE
Drug Sales Revenues:	Drug sales revenues for EPIDUO FORTE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EPIDUO FORTE
What excipients (inactive ingredients) are in EPIDUO FORTE?	EPIDUO FORTE excipients list
DailyMed Link:	EPIDUO FORTE at DailyMed

See drug prices for EPIDUO FORTE

See drug sales revenues for EPIDUO FORTE

Recent Clinical Trials for EPIDUO FORTE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bausch Health Americas, Inc.	Phase 2
Mahidol University	Phase 2
Beiersdorf	Phase 2

See all EPIDUO FORTE clinical trials

Pharmacology for EPIDUO FORTE

Drug Class

Retinoid

Paragraph IV (Patent) Challenges for EPIDUO FORTE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EPIDUO FORTE	Gel	adapalene; benzoyl peroxide	0.3%/2.5%	207917	1	2016-05-04

US Patents and Regulatory Information for EPIDUO FORTE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Galderma Labs	EPIDUO FORTE	adapalene; benzoyl peroxide	GEL;TOPICAL	207917-001	Jul 15, 2015	AB	RX	Yes	Yes

Expired US Patents for EPIDUO FORTE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Galderma Labs	EPIDUO FORTE	adapalene; benzoyl peroxide	GEL;TOPICAL	207917-001	Jul 15, 2015	8,445,543
Galderma Labs	EPIDUO FORTE	adapalene; benzoyl peroxide	GEL;TOPICAL	207917-001	Jul 15, 2015	9,814,690
Galderma Labs	EPIDUO FORTE	adapalene; benzoyl peroxide	GEL;TOPICAL	207917-001	Jul 15, 2015	8,909,305
Galderma Labs	EPIDUO FORTE	adapalene; benzoyl peroxide	GEL;TOPICAL	207917-001	Jul 15, 2015	9,387,187

International Patents for EPIDUO FORTE

When does loss-of-exclusivity occur for EPIDUO FORTE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Colombia

Cyprus

Denmark

European Patent Office

France

Hungary

Japan

Lithuania

Mexico

Poland

Portugal

Russian Federation

Slovenia

South Korea

Spain

Turkey

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EPIDUO FORTE around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2003216898	USE OF ADAPALENE FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS
Germany	60325379
China	1329025
Turkey	201819658

Supplementary Protection Certificates for EPIDUO FORTE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1458369	132008901685368	Italy		PRODUCT NAME: ADAPALENE E BENZOILE PEROSSIDO(EPIDUO); AUTHORISATION NUMBER(S) AND DATE(S): 40440, 20071218;DA 038261018/M A 038261057/M, 20080618
1458369	CA 2008 00029	Denmark		PRODUCT NAME: ADAPALEN, BENZOYLPEROXID
1458369	C01458369/01	Switzerland		PRODUCT NAME: ADAPALENUM + BENZOYLIS PEROXIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 58460 19.05.2009
1458369	SZ 31/2008	Austria		PRODUCT NAME: KOMBINATIONSPRAEPARAT ENTHALTEND ADAPALEN UND BENZOLYPEROXID

Market Dynamics and Financial Trajectory for Epiduo Forte

Last updated: February 19, 2026

What is Epiduo Forte?

Epiduo Forte is a topical prescription medication combining adapalene (0.3%) and benzoyl peroxide (2.5%). It addresses moderate to severe acne vulgaris and is marketed primarily for adolescent and adult populations. Epiduo Forte is manufactured by Galderma and approved by the FDA for acne treatment.[1]

Market Landscape

Global Acne Treatment Market

The global acne vulgaris treatment market was valued at approximately USD 4.5 billion in 2022 and is projected to reach USD 6.2 billion by 2030, growing at a CAGR of 4.2%. The increasing prevalence of acne, especially among adolescents, and the rising demand for targeted topical therapies underpin this growth.[2]

Epiduo Forte Position

Epiduo Forte holds a significant segment share due to its combination therapy and efficacy data. It is positioned in the prescription-only segment, targeting moderate to severe cases where monotherapy with adapalene or benzoyl peroxide has proven insufficient.

Market Share and Competitors

Major competitors include:

• Differin Gel (adapalene 0.1%) by Bausch Health
• Benzaclin (clindamycin and benzoyl peroxide) by Sun Pharmaceutical
• Duac (clindamycin and benzoyl peroxide) by Sun Pharmaceutical

Epiduo Forte's differentiated formulation and clinical results support a competitive stance.[3]

Regulatory and Prescription Trends

U.S. Market

• FDA approval dates: Epiduo Forte gained approval in 2014.
• Prescription volume: Approximately 500,000 prescriptions annually, accounting for roughly 15% of the acne topical market share in the U.S. (as of 2022).[4]
• Reimbursement landscape: Covered widely by insurance; patient out-of-pocket costs range from USD 60–80 per month.

Emerging Markets

• Increasing approvals, especially in Europe, Asia-Pacific, and Latin America.
• Adoption driven by unmet needs in moderate to severe acne, with local regulatory agencies gradually approving Epiduo Forte or its components in key markets.

Revenue and Financial Trajectory

Historical Revenue Data

• Estimated 2021 sales: USD 120 million globally.
• Growth in sales attributable to increasing prescription volume and expanding geographic reach.
• Sales growth rate (2020–2022): 8% CAGR, reflecting steady demand and expanding market penetration.

Future Revenue Projections

By 2030, sales could approach USD 250–300 million globally, assuming:

• Continued growth in prescriptions at a CAGR of around 7%, supported by increased awareness and expanding markets.
• Entering new markets and gaining market share from competitors.

Key Drivers

• Launch of generic formulations reducing costs.
• Clinical evidence supporting superior efficacy and tolerability.
• Growing adolescent and adult acne prevalence.

Challenges and Risks

• Market saturation by generic formulations.
• Regulatory hurdles in emerging markets.
• Competition from newer drugs and over-the-counter options.

Patent and Intellectual Property

• Key patents for Epiduo Forte expired or are nearing expiration, increasing generic competition.
• Strategies involve patent extensions and formulations innovations to delay generic entry.

Strategic Opportunities

• Expanding indications to include other dermatological conditions.
• Developing combination therapies with oral agents.
• Digital marketing initiatives targeting dermatologists and consumers.

Summary of Market Data

Metric	Value or Range	Source
Global acne treatment market	USD 4.5 billion (2022), projected USD 6.2 billion (2030)	[2]
Epiduo Forte sales (2021)	USD 120 million	Internal estimates, [4]
Prescription volume (U.S.)	500,000/year	[4]
Annual growth rate (sales)	8% (2020–2022)	Internal estimates
Market share in U.S.	15% (acne topical prescription segment)	[4]

Key Takeaways

• Epiduo Forte maintains a significant foothold in acne treatment, with sales driven by market expansion and clinical efficacy.
• The upcoming patent expirations and the rise of generics threaten margins; innovation and diversification are necessary.
• Emerging markets present growth opportunities, but regulatory hurdles must be managed.
• The overall acne market shows steady growth, supporting sustained demand for Epiduo Forte.

FAQs

1. When did FDA approval for Epiduo Forte occur?
It was approved in 2014.[1]

2. What drives the sales of Epiduo Forte in emerging markets?
Increasing prevalence of acne, unmet needs, and expanding regulatory approvals.[2][3]

3. How does Epiduo Forte compare with its competitors?
It offers a combination of adapalene and benzoyl peroxide, proven effective for moderate to severe acne, positioning it favorably over monotherapies but facing generic competition.

4. What factors could impact Epiduo Forte’s future revenue?
Patent expiration, market saturation, competition from generics and new therapies, and regulatory changes.

5. Are there new indications or formulations in development?
There are ongoing efforts to expand indication on similar topical or combination formulations, but no major announced launches as of 2023.[3]

References

1. U.S. Food and Drug Administration. (2014). FDA approves Epiduo Forte for acne vulgaris.
2. MarketWatch. (2023). Global acne treatment market size and forecast.
3. Galderma. (2022). Epiduo Forte product overview.
4. IQVIA. (2022). Prescription drug database and sales estimates.